Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001570 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer
A Phase 1 study of Neoplasm Metastasis and Kidney Neoplasms, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT00001570: Completed Phase 1 study of Neoplasm Metastasis and Kidney Neoplasms, sponsored by National Cancer Institute (NCI).
NCT00001570 is a Phase 1 study of Neoplasm Metastasis and Kidney Neoplasms that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 46 participants, below the 415-participant average among 41 other Neoplasm Metastasis trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001570, a Phase 1 study of Neoplasm Metastasis and Kidney Neoplasms, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
Bolus PSC 833 is administered on Day 1 simultaneously with initiation of 24 hour continuous infusion of PSC 833, followed by another continuous infusion lasting an additional 6 days. To ensure the safety of a 7 day infusion of PSC 833, one patient is treated for 5 days and a second for 6 days, before the first cohort is enrolled. Vinblastine is administered in escalating doses on days 2-5. At least 3 patients are entered at each dose level. The MTD will be defined as the dose immediately below that at which 2 patients experience dose limiting toxicity. Treatment continues every 28 days.
Conditions Studied
Interventions
- DRUG vinblastine
- DRUG PSC 833
Study Locations (1)
Maryland
- National Cancer Institute (NCI) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 1997-02 |
| Est. Completion | 2001-01 |
| Phase | Phase 1 |
What the finished NCT00001570 record still lists
NCT00001570 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 415-participant average among 41 other Neoplasm Metastasis trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Neoplasm Metastasis appearing as the primary indexed condition, and to 2 interventions - of which vinblastine is the first listed.
NCT00001570 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00001570 about?
NCT00001570 is a clinical study titled "A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer". Bolus PSC 833 is administered on Day 1 simultaneously with initiation of 24 hour continuous infusion of PSC 833, followed by another continuous infusion lasting an additional 6 days. To ensure the safety of a 7 day infusion of PSC 833, one patient is treated for 5 days and a second for 6 days, befor...
What is the current status of trial NCT00001570?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 1997-02. Estimated completion is 2001-01.
What conditions does trial NCT00001570 study?
This clinical trial studies the following conditions: Neoplasm Metastasis, Kidney Neoplasms.
What interventions are being tested in trial NCT00001570?
The interventions under investigation include: vinblastine (DRUG), PSC 833 (DRUG).
Who is sponsoring clinical trial NCT00001570?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001570 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasm Metastasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00001570's enrollment target sits among peer trials
46 31st of 41 higher than 10 of 41 other Neoplasm Metastasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasm Metastasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
RECRUITING · Phase 1
-
A Study of LY4175408 in Participants With Advanced Cancer
RECRUITING · Phase 1
-
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RECRUITING · Phase 1
-
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
RECRUITING · Phase 1
-
A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia